PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control of editorial content. More information is available here »

News

Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid PCSK9 inhibitors are unlikely to contribute to mood disorders PCSK9 inhibitors may be effective treatment for PAD PACMAN-AMI: new data on lesion-level effects of lipid lowering AT-TARGET-IT shows reduced CV risk with early PCSK9i in ACS

3rd Closed Scientific Expert Meeting of the Editorial Board

28 August 2015, London, UK (Educational supporters)

ApoB-containing lipoproteins and the pathophysiology of atherosclerotic vascular disease: update

Jan Boren

Posted on 12 January 2016 | Posted by Jan Boren | Posted in Webcasts, 3rd Closed Scientific Expert Meeting of the Editorial Board

Innovative PCSK9-targeted therapeutics: siRNA

Stephen Nicholls

Posted on 20 October 2015 | Posted by Steve Nicholls | Posted in Webcasts, 3rd Closed Scientific Expert Meeting of the Editorial Board, 3rd Closed Expert Meeting of the Editorial Board 2015

Monoclonal Antibodies: New options for diagnosis and therapy in CVD

Dario Neri

Posted on 20 October 2015 | Posted by Dario Neri | Posted in Webcasts, 3rd Closed Scientific Expert Meeting of the Editorial Board, 3rd Closed Expert Meeting of the Editorial Board 2015

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation